Please note: The services and contact information described below are available in the US only. For information on obtaining Sucraid® (sacrosidase) Oral Solution for patients located outside of the US, please see Non-US Orders section.
As a specialty pharmaceutical product for a niche, orphan patient population, Sucraid® is not available through traditional retail pharmacies. QOL Medical, the maker of Sucraid®, uses an exclusive specialty pharmacy provider that ships therapy directly to the patient’s home or physician’s office. All shipments are refrigerated. This arrangement ensures that each patient receives his/her medication in a timely manner. This process applies to both the prescription product as well as the therapeutic response dose shipments.
Patient access to specialty, niche pharmaceuticals is often a complex process influenced by many factors including the extent of a patient’s insurance coverage, copay requirements, and contracts between the patient’s insurance provider and the drug benefit administrator or pharmacy benefits manager. Exclusive specialty pharmacy distribution channels are designed specifically to support such complexities. Beyond just arranging for direct shipment of Sucraid® (sacrosidase) Oral Solution to the patient’s home, the real benefit of using an exclusive specialty pharmacy provider is that it provides a full range of patient access and reimbursement support services. These services, which help healthcare providers, caregivers, and/or patients access therapy, include:
Upon enrollment in the Sucraid® program, the physician’s office is contacted by a SucraidASSIST™ (Access and Support Services in Sucraid® Therapy) team member who will explain the available services, research reimbursement, and coordinate shipment of the first order of Sucraid® with the patient. Each month thereafter, the patient is contacted by a SucraidASSIST™ team member who will arrange additional shipments and monitor patient refills.
The specialty pharmacy provider model and supporting services facilitate patient access to Sucraid® to the fullest extent allowable by both federal and state laws.